| 
RESULTS OF THE CELEBREX CLINICAL TRIAL IN
ALS
October 25, 2004—The Northeast ALS consortium completed a study
of Celebrex in 300 people with ALS treated for one year.
At 800 mg per day, Celebrex was safe and well tolerated. Celebrex did
not have any demonstrated beneficial effects on ALS disease course.
Studies are underway to assess whether Celebrex as used in this study
had the predicted pharmacologic effects in the treated subjects. The study
results will be presented at the International Motor Neuron Disease Association
on December 3rd, 2004.
More details on the study are available at
Packard Center Commentary: RESULTS OF CELEBREX
TRIAL REPORTED
and on the MDA website: http://www.mdausa.org/research/041026celebrex.html
For information on clinical trials at the ALS Clinic at Johns Hopkins,
please visit www.alscenter.org/clinical_trials/
or contact Lora Clawson, MSN, CRNP, Director of ALS Clinical Services,
at 410-955-8511.
>>
more press releases
|
